Evolutec begins phase 2b trial of rEV131 in allergic rhinitis

By Lisa Kerner

Charlotte, N.C., June 13 - Evolutec Group plc began a 300-patient phase 2b trial of rEV131 in allergic rhinitis following receipt of an unconditional "No Objection Letter" from Health Canada, according to a company news release.

This multi-dose, double-blind trial held in Toronto will determine the duration of action of rEV131 administered as a nasal spray. Patients will be exposed to high levels of ragweed pollen for periods in excess of 12 hours.

The primary endpoint is the sum of symptom scores after seven days of twice daily dosing, the company said.

Evolutec's rEV131 is a recombinant derived from a naturally occurring molecule identified in ticks and parasites.

The U.S. allergic rhinitis market is estimated at $6.6 billion.

Evolutec, based in Reading, U.K, is a clinical-stage biopharmaceutical company with a focus on allergy, inflammation and auto-immune diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.